PARP inhibitors have been shown to activate STING and upregulate PD-L1 across cancer models regardless of BRCA mutation status, leading to synergy with PD-L1 inhibitors in preclinical mouse studies [59,60,61,62,63]. Here, PARP1 is linked to cancer.